Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Middeke

Showing results (151-160 of 158) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 158 results.
Leukemia & Lymphoma|January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysisJan M Middeke, Raphael Teipel, Christoph Röllig, et al.
Blood Advances|January 23, 2023
Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemiaFalk Heidenreich, Bose Falk, Henning Baldauf, et al.
Cancers|September 27, 2025
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity TherapyKatja Krüger, Razif Gabdoulline, Martin Wichmann, et al.
Bone Marrow Transplantation|November 25, 2023
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP studyA Mussetti, B Rius-Sansalvador, V Moreno, et al.
Haematologica|August 16, 2019
<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemiaSebastian Stasik, Jan M Middeke, Michael Kramer, et al.
Blood Advances|August 30, 2021
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaSebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, et al.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
Blood Advances|November 18, 2021
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter studyJan M Middeke, Klaus H Metzeler, Christoph Röllig, et al.
Pageof 16

Showing results (151-160 of 158) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 158 results.
Leukemia & Lymphoma|January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysisJan M Middeke, Raphael Teipel, Christoph Röllig, et al.
Blood Advances|January 23, 2023
Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemiaFalk Heidenreich, Bose Falk, Henning Baldauf, et al.
Cancers|September 27, 2025
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity TherapyKatja Krüger, Razif Gabdoulline, Martin Wichmann, et al.
Bone Marrow Transplantation|November 25, 2023
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP studyA Mussetti, B Rius-Sansalvador, V Moreno, et al.
Haematologica|August 16, 2019
<i>EZH2</i> mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemiaSebastian Stasik, Jan M Middeke, Michael Kramer, et al.
Blood Advances|August 30, 2021
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaSebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, et al.
Journal of Hematology & Oncology|September 5, 2022
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationDesiree Kunadt, Sebastian Stasik, Klaus H Metzeler, et al.
Blood Advances|November 18, 2021
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter studyJan M Middeke, Klaus H Metzeler, Christoph Röllig, et al.
Pageof 16